VERV Verve Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: VERV

Price (delayed)

$6.285

Market cap

$525.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.12

Enterprise value

$379.31M

Highlights
VERV's gross profit has soared by 54% since the previous quarter
Verve Therapeutics's revenue has soared by 54% from the previous quarter
The net income has declined by 27% year-on-year and by 3.8% since the previous quarter
Verve Therapeutics's EPS has decreased by 7% YoY
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of VERV
Market
Shares outstanding
83.62M
Market cap
$525.55M
Enterprise value
$379.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.67
Price to sales (P/S)
34.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.26
Earnings
Revenue
$11.76M
EBIT
-$199.79M
EBITDA
-$187.55M
Free cash flow
-$158.83M
Per share
EPS
-$3.12
Free cash flow per share
-$2.47
Book value per share
$9.4
Revenue per share
$0.18
TBVPS
$11.73
Balance sheet
Total assets
$752.69M
Total liabilities
$153.19M
Debt
$64.72M
Equity
$599.5M
Working capital
$600.94M
Liquidity
Debt to equity
0.11
Current ratio
17.24
Quick ratio
17.15
Net debt/EBITDA
0.78
Margins
EBITDA margin
-1,595.1%
Gross margin
100%
Net margin
-1,701.5%
Operating margin
-1,897.6%
Efficiency
Return on assets
-30.9%
Return on equity
-39.3%
Return on invested capital
-35.3%
Return on capital employed
-27.9%
Return on sales
-1,699.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VERV stock price

How has the Verve Therapeutics stock price performed over time
Intraday
-4.48%
1 week
-5.63%
1 month
-52.24%
1 year
-60.02%
YTD
-54.91%
QTD
-52.67%

Financial performance

How have Verve Therapeutics's revenue and profit performed over time
Revenue
$11.76M
Gross profit
$11.76M
Operating income
-$223.12M
Net income
-$200.07M
Gross margin
100%
Net margin
-1,701.5%
VERV's net margin has surged by 79% year-on-year and by 33% since the previous quarter
The operating margin has soared by 78% YoY and by 33% from the previous quarter
VERV's gross profit has soared by 54% since the previous quarter
Verve Therapeutics's revenue has soared by 54% from the previous quarter

Growth

What is Verve Therapeutics's growth rate over time

Valuation

What is Verve Therapeutics stock price valuation
P/E
N/A
P/B
0.67
P/S
34.3
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
32.26
Verve Therapeutics's EPS has decreased by 7% YoY
The P/B is 63% below the last 4 quarters average of 1.9
Verve Therapeutics's equity has increased by 30% from the previous quarter and by 9% YoY
The price to sales (P/S) is 78% less than the last 4 quarters average of 166.5
Verve Therapeutics's revenue has soared by 54% from the previous quarter

Efficiency

How efficient is Verve Therapeutics business performance
Verve Therapeutics's return on sales has surged by 79% YoY and by 33% QoQ
VERV's return on invested capital is up by 17% year-on-year but it is down by 4.7% since the previous quarter
VERV's ROE is down by 8% YoY

Dividends

What is VERV's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VERV.

Financial health

How did Verve Therapeutics financials performed over time
The total assets has grown by 23% from the previous quarter and by 11% YoY
The quick ratio rose by 20% since the previous quarter and by 7% year-on-year
VERV's debt is 89% smaller than its equity
Verve Therapeutics's equity has increased by 30% from the previous quarter and by 9% YoY
VERV's debt to equity is down by 21% since the previous quarter and by 15% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.